WealthTrust Axiom’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

WealthTrust Axiom’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-16,396	Closed	-$384	–	268
2025 Q1	$384	Hold	16,396	–	–	﹤0.01%	255
2024 Q4	$2.64K	Hold	16,396	–	–	﹤0.01%	254
2024 Q3	$3.79K	Buy	16,396 +5,000	+44%	+$1.83K	﹤0.01%	263
2024 Q2	$6.2K	Hold	11,396	–	–	﹤0.01%	255
2024 Q1	$11.6K	Buy	+11,396	New	+$8.32K	﹤0.01%	261

WealthTrust Axiom's VIRX Position: Q2 2025 in Review

WealthTrust Axiom sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2025, closing a stake of 16,396 shares — an estimated $384 sold.

WealthTrust Axiom first reported a position in VIRX in Q1 2024 and held it in 5 quarters. The position peaked at $11.6K in Q1 2024. 0 funds tracked by Wall St. Rank hold VIRX as of Q2 2025.

WealthTrust Axiom reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
WealthTrust Axiom sold 16,396 Viracta Therapeutics, Inc. Common Stock shares in Q2 2025, an estimated $384.
WealthTrust Axiom first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2024 and held it in 5 quarters.
WealthTrust Axiom's Viracta Therapeutics, Inc. Common Stock position peaked at $11.6K in Q1 2024.
0 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2025.

Based on WealthTrust Axiom's 13F filing for Q2 2025, filed 13 Aug 2025.